Skip to main content
Erschienen in: Urolithiasis 2/2018

28.06.2017 | Review

Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries

verfasst von: Jamsheer Jehangir Talati, Sally-Anne Hulton, Sander F. Garrelfs, Wajahat Aziz, Shoaib Rao, Amanullah Memon, Zafar Nazir, Raziuddin Biyabani, Saqib Qazi, Iqbal Azam, Aysha Habib Khan, Jamil Ahmed, Lena Jafri, Mohammad Zeeshan

Erschienen in: Urolithiasis | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Primary hyperoxalurias (PH) are devastating, autosomal recessive diseases causing renal stones. Undifferentiated hyperoxaluria is seen in up to 43% of Pakistani paediatric stone patients. High rates of consanguinity in Pakistan suggest significant local prevalence. There is no detailed information regarding number of cases, clinical features, and genetics in Pakistan-origin (P-o) patients. We reviewed available information on P-o PH patients recorded in the literature as well as from two major PH registries (the Rare Kidney Stone Consortium PH Registry (RKSCPHR) and the OxalEurope PH Registry (OxER); and the Aga Khan University Hospital in Pakistan. After excluding overlaps, we noted 217 P-o PH subjects (42 in OxER and 4 in RKSCPHR). Presentations were protean. Details of mutations were available for 94 patients of 201 who had genetic analyses. Unique mutations were noted. Mutation [c.508G>A (p. Gly170Arg)] (present in up to 25% in the West) was reported in only one case. In one series, only 30% had mutations on exons 1,4,7 of AGXT. Of 42 P-o patients in OxER, 52.4% were PH1, 45.2% PH2, and 2.4% PH3. Of concern is that diagnosis was made after renal transplant rejection (four cases) and on bone-marrow aspiration (in five). Lack of consideration of PH as a diagnosis, late diagnosis, and loss of transplanted kidneys mandates that PH be searched for diligently. Mutation analysis will need to extend to all exons and include PH 1,2,3. There is a need to spread awareness and identify patients through a scoring or screening system that alerts physicians to consider a diagnosis of PH.
Literatur
2.
3.
Zurück zum Zitat Cochat P, Nogueira PCK, Mahmoud MA, Jamieson NV, Scheinman JI, Rolland M-O (1999) Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr 135(6):746–750CrossRefPubMed Cochat P, Nogueira PCK, Mahmoud MA, Jamieson NV, Scheinman JI, Rolland M-O (1999) Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr 135(6):746–750CrossRefPubMed
4.
Zurück zum Zitat Spasovski G, Beck BB, Blau N, Hoppe B, Tasic V (2010) Late diagnosis of primary hyperoxaluria after failed kidney transplantation. Int Urol Nephrol 42(3):825–829CrossRefPubMed Spasovski G, Beck BB, Blau N, Hoppe B, Tasic V (2010) Late diagnosis of primary hyperoxaluria after failed kidney transplantation. Int Urol Nephrol 42(3):825–829CrossRefPubMed
5.
Zurück zum Zitat Hashmi M (1997) Frequency of consanguinity and its effect on congenital malformation-a hospital based study. J Pakistan Med Assoc 47:75–77 Hashmi M (1997) Frequency of consanguinity and its effect on congenital malformation-a hospital based study. J Pakistan Med Assoc 47:75–77
6.
Zurück zum Zitat Kamoun A, Lakhoua R (1996) End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. Pediatr Nephrol 10(4):479–482CrossRefPubMed Kamoun A, Lakhoua R (1996) End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. Pediatr Nephrol 10(4):479–482CrossRefPubMed
8.
Zurück zum Zitat Khaliq S, Abid A, Shahid S, Hashmi S, Sultan S, Aziz T, Rizvi SAH, Mehdi SQ (2013) Comprehensive mutation screening of the AGXT gene in patients with primary hyperoxaluria type-1. Paper presented at the 63rd annual meeting of the American Society of Human Genetics, Boston Khaliq S, Abid A, Shahid S, Hashmi S, Sultan S, Aziz T, Rizvi SAH, Mehdi SQ (2013) Comprehensive mutation screening of the AGXT gene in patients with primary hyperoxaluria type-1. Paper presented at the 63rd annual meeting of the American Society of Human Genetics, Boston
9.
Zurück zum Zitat Sajid R, Moiz B, Adil S, Khurshid M (2009) Calcium oxalate crystals in the bone marrow. Br J Haematol 146(1):1CrossRefPubMed Sajid R, Moiz B, Adil S, Khurshid M (2009) Calcium oxalate crystals in the bone marrow. Br J Haematol 146(1):1CrossRefPubMed
10.
Zurück zum Zitat Johnson SA, Rumsby G, Cregeen D, Hulton S-A (2002) Primary hyperoxaluria type 2 in children. Pediatr Nephrol 17(8):597–601CrossRefPubMed Johnson SA, Rumsby G, Cregeen D, Hulton S-A (2002) Primary hyperoxaluria type 2 in children. Pediatr Nephrol 17(8):597–601CrossRefPubMed
11.
Zurück zum Zitat Illum N, Lavard L, Danpure C, Horn T, AErenlund JH, Skovby F (1991) Primary hyperoxaluria type 1: clinical manifestations in infancy and prenatal diagnosis. Child Nephrol Urol 12(4):225–227 Illum N, Lavard L, Danpure C, Horn T, AErenlund JH, Skovby F (1991) Primary hyperoxaluria type 1: clinical manifestations in infancy and prenatal diagnosis. Child Nephrol Urol 12(4):225–227
12.
Zurück zum Zitat Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6(9):2289–2295CrossRefPubMedPubMedCentral Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6(9):2289–2295CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Chanchlani R, Sinha A, Gulati A, Agarwal V, Bagga A (2012) Common mutation underlying primary hyperoxaluria type1 in three Indian children. Indian J Nephrol 22(6):459CrossRefPubMedPubMedCentral Chanchlani R, Sinha A, Gulati A, Agarwal V, Bagga A (2012) Common mutation underlying primary hyperoxaluria type1 in three Indian children. Indian J Nephrol 22(6):459CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat von Schnakenburg C, Rumsby G (1997) Identification of new mutations in primary hyperoxaluria type 1 (PH1). J Nephrol 11:15–17 von Schnakenburg C, Rumsby G (1997) Identification of new mutations in primary hyperoxaluria type 1 (PH1). J Nephrol 11:15–17
15.
Zurück zum Zitat von Schnakenburg C, Hulton SA, Milford DV, Roper HP, Rumsby G (1998) Variable presentation of primary hyperoxaluria type 1 in 2 patients homozygous for a novel combined deletion and insertion mutation in exon 8 of the AGXT gene. Nephron 78(4):485–488CrossRef von Schnakenburg C, Hulton SA, Milford DV, Roper HP, Rumsby G (1998) Variable presentation of primary hyperoxaluria type 1 in 2 patients homozygous for a novel combined deletion and insertion mutation in exon 8 of the AGXT gene. Nephron 78(4):485–488CrossRef
16.
Zurück zum Zitat Chu W (2011) Case report renal and musculoskeletal manifestations of primary hyperoxaluria in a girl 女孩原發性高尿酸血症的腎臟及肌肉骨胳的臨床表現. HK J Paediatr 16(1):41–46 Chu W (2011) Case report renal and musculoskeletal manifestations of primary hyperoxaluria in a girl 女孩原發性高尿酸血症的腎臟及肌肉骨胳的臨床表現. HK J Paediatr 16(1):41–46
17.
Zurück zum Zitat Perera MTP, Sharif K, Lloyd C, Foster K, Hulton SA, Mirza DF, McKiernan PJ (2011) Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transpl 26(1):354–359CrossRef Perera MTP, Sharif K, Lloyd C, Foster K, Hulton SA, Mirza DF, McKiernan PJ (2011) Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transpl 26(1):354–359CrossRef
18.
Zurück zum Zitat Takayama T, Takaoka N, Nagata M, Johnin K, Okada Y, Tanaka S, Kawamura M, Inokuchi T, Ohse M, Kuhara T (2014) Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. Clin Genet 86(4):342–348CrossRefPubMed Takayama T, Takaoka N, Nagata M, Johnin K, Okada Y, Tanaka S, Kawamura M, Inokuchi T, Ohse M, Kuhara T (2014) Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. Clin Genet 86(4):342–348CrossRefPubMed
19.
Zurück zum Zitat Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E (2009) Mutation update. Hum Mutat 30:910–917CrossRefPubMed Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E (2009) Mutation update. Hum Mutat 30:910–917CrossRefPubMed
20.
Zurück zum Zitat Harambat J, Fargue S, Acquaviva C, Gagnadoux M-F, Janssen F, Liutkus A, Mourani C, Macher M-A, Abramowicz D, Legendre C (2010) Genotype–phenotype correlation in primary hyperoxaluria type 1: the p. Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77(5):443–449CrossRefPubMed Harambat J, Fargue S, Acquaviva C, Gagnadoux M-F, Janssen F, Liutkus A, Mourani C, Macher M-A, Abramowicz D, Legendre C (2010) Genotype–phenotype correlation in primary hyperoxaluria type 1: the p. Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77(5):443–449CrossRefPubMed
21.
Zurück zum Zitat Mandrile G, van Woerden CS, Berchialla P, Beck BB, Bourdain CA, Hulton S-A, Rumsby G (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86(6):1197–1204CrossRefPubMed Mandrile G, van Woerden CS, Berchialla P, Beck BB, Bourdain CA, Hulton S-A, Rumsby G (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86(6):1197–1204CrossRefPubMed
22.
Zurück zum Zitat Coulter-Mackie MB, Rumsby G (2004) Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis. Mol Genet Metab 83(1):38–46CrossRefPubMed Coulter-Mackie MB, Rumsby G (2004) Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis. Mol Genet Metab 83(1):38–46CrossRefPubMed
23.
Zurück zum Zitat Danpure CJ (2005) Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transpl 20(8):1525–1529CrossRef Danpure CJ (2005) Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transpl 20(8):1525–1529CrossRef
24.
Zurück zum Zitat Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Consortium RKS (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26(10):2559–70. doi:10.1681/ASN.2014070698 Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Consortium RKS (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26(10):2559–70. doi:10.​1681/​ASN.​2014070698
25.
Zurück zum Zitat Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21(2):162–172. doi:10.1038/ejhg.2012.139 CrossRefPubMed Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21(2):162–172. doi:10.​1038/​ejhg.​2012.​139 CrossRefPubMed
26.
Zurück zum Zitat Hutchesson A, Bundey S, Preece M, Hall S, Green A (1998) A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet 35(5):366–370CrossRefPubMedPubMedCentral Hutchesson A, Bundey S, Preece M, Hall S, Green A (1998) A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet 35(5):366–370CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Bittles AH (2001) Consanguinity and its relevance to clinical genetics. Clin Genet 60(2):89–98CrossRefPubMed Bittles AH (2001) Consanguinity and its relevance to clinical genetics. Clin Genet 60(2):89–98CrossRefPubMed
29.
Zurück zum Zitat Overall A, Ahmad M, Nichols R (2002) The effect of reproductive compensation on recessive disorders within consanguineous human populations. Heredity 88(6):474–479CrossRefPubMed Overall A, Ahmad M, Nichols R (2002) The effect of reproductive compensation on recessive disorders within consanguineous human populations. Heredity 88(6):474–479CrossRefPubMed
30.
Zurück zum Zitat Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J (2017) An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 28(2):494–503. doi:10.1681/ASN.2016030338 CrossRefPubMed Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J (2017) An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 28(2):494–503. doi:10.​1681/​ASN.​2016030338 CrossRefPubMed
31.
Zurück zum Zitat Gambaro G, Ferraro MP, D’Addessi A (2011) Ayurvedic medicine and NADPH oxidase: a possible approach to the prevention of ESRD in hyperoxaluria. Nephrol Dial Transpl 26(6):1759–1761CrossRef Gambaro G, Ferraro MP, D’Addessi A (2011) Ayurvedic medicine and NADPH oxidase: a possible approach to the prevention of ESRD in hyperoxaluria. Nephrol Dial Transpl 26(6):1759–1761CrossRef
32.
Zurück zum Zitat Naderi G, Tabassomi F, Latif A, Ganji M (2015) Primary hyperoxaluria type 1 diagnosed after kidney transplantation: the importance of pre-transplantation metabolic screening in recurrent urolithiasis. Saudi J Kidney Dis Transpl 26(4):783CrossRefPubMed Naderi G, Tabassomi F, Latif A, Ganji M (2015) Primary hyperoxaluria type 1 diagnosed after kidney transplantation: the importance of pre-transplantation metabolic screening in recurrent urolithiasis. Saudi J Kidney Dis Transpl 26(4):783CrossRefPubMed
33.
Zurück zum Zitat Clifford-Mobley O, Hewitt L, Rumsby G (2016) Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann Clin Biochem 53(4):485–494CrossRefPubMed Clifford-Mobley O, Hewitt L, Rumsby G (2016) Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann Clin Biochem 53(4):485–494CrossRefPubMed
35.
Zurück zum Zitat Alsuwaida A, Hayat A, Alwakeel JS (2007) Oxalosis presenting as early renal allograft failure. Saudi J Kidney Dis Transpl 18(2):253PubMed Alsuwaida A, Hayat A, Alwakeel JS (2007) Oxalosis presenting as early renal allograft failure. Saudi J Kidney Dis Transpl 18(2):253PubMed
36.
Zurück zum Zitat Hassan K, Qaisrani JH, Qazi H, Naseem L, Zaheer HA, Zafar T (2006) Oxalosis in the bone and bone marrow. Int J Pathol 4(2):129–131 Hassan K, Qaisrani JH, Qazi H, Naseem L, Zaheer HA, Zafar T (2006) Oxalosis in the bone and bone marrow. Int J Pathol 4(2):129–131
37.
Zurück zum Zitat Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87(3):623–631CrossRefPubMed Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87(3):623–631CrossRefPubMed
Metadaten
Titel
Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries
verfasst von
Jamsheer Jehangir Talati
Sally-Anne Hulton
Sander F. Garrelfs
Wajahat Aziz
Shoaib Rao
Amanullah Memon
Zafar Nazir
Raziuddin Biyabani
Saqib Qazi
Iqbal Azam
Aysha Habib Khan
Jamil Ahmed
Lena Jafri
Mohammad Zeeshan
Publikationsdatum
28.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 2/2018
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-017-0996-8

Weitere Artikel der Ausgabe 2/2018

Urolithiasis 2/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.